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TweakR is a TNF receptor family member, whose natural ligand is the multifunctional
cytokine TWEAK. The growth inhibitory activity observed following TweakR stimulation
in certain cancer cell lines and the overexpression ofTweakR in many solid tumor types led
to the development of enavatuzumab (PDL192), a humanized IgG1 monoclonal antibody
to TweakR. The purpose of this study was to determine the mechanism of action of ena-
vatuzumab’s tumor growth inhibition and to provide insight into the biology behindTweakR
as a cancer therapeutic target. A panel of 105 cancer lines was treated with enavatuzumab
in vitro; and 29 cell lines of varying solid tumor backgrounds had >25% growth inhibition
in response to the antibody. Treatment of sensitive cell lines with enavatuzumab resulted
in the in vitro and in vivo (xenograft) activation of both classical (p50, p65) and non-classical
(p52, RelB) NFκB pathways. Using NFκB DNA binding functional ELISAs and microarray
analysis, we observed increased activation of NFκB subunits and NFκB-regulated genes in
sensitive cells over that observed in resistant cell lines. Inhibiting NFκB subunits (p50, p65,
RelB, p52) and upstream kinases (IKK1, IKK2) with siRNA and chemical inhibitors consis-
tently blocked enavatuzumab’s activity. Furthermore, enavatuzumab treatment resulted in
NFκB-dependent reduction in cell division as seen by the activation of the cell cycle inhibitor
p21 both in vitro and in vivo. The finding that NFκB drives the growth inhibitory activity of
enavatuzumab suggests that targeting TweakR with enavatuzumab may represent a novel
cancer treatment strategy.
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INTRODUCTION
TweakR (Fn14, TNFRSF12A) is a member of the TNF receptor
superfamily which is activated by its ligand, the cytokine TWEAK
(TNFSF12). TweakR is the smallest member of the TNFR super-
family (1). It lacks the death domain associated with other TNFR
members such as TNFR1, Fas, and TRAIL-R1, but it does contain
a cytoplasmic TNFR-associated factor (TRAF) binding site allow-
ing recruitment of TRAF adapter proteins which are vital for many
of the intracellular signaling events that occur downstream of the
TNFR family (2, 3).
TweakR was initially described as an inducer of apoptosis in
certain cancer cell lines upon stimulation with its ligand TWEAK
(4). TweakR also has a role in diverse biological processes such as
inflammation, tissue repair, angiogenesis, and cell migration (5–8).
The signaling pathways downstream of TweakR have been eluci-
dated for some of these biological functions. The ERK, JNK, and
NFκB pathways have been shown to be upregulated by TWEAK in
endothelial cells, while the NFκB pathway appears to be involved
in TWEAK-stimulated inflammation and cell survival (9–11).
TWEAK and agonist TweakR antibodies have also been shown
to induce cell death in certain tumor cell lines through multi-
ple mechanisms, including caspase-dependent and -independent
apoptosis and necrosis (3, 12–14). However, in other tumor cell
lines, TweakR stimulation leads to a slowed growth effect, not cell
death (15). The signaling pathways mediating that phenotype have
not been determined.
The ability of TweakR stimulation to inhibit the growth of cer-
tain cancer cell lines, as well as the observation that TweakR is
over-expressed in many cancers (3, 16) suggested that an antibody
targeting TweakR could be a potential therapeutic agent. Ena-
vatuzumab (formerly PDL192), a humanized monoclonal IgG1,
which binds to and activates TweakR, has been shown to have
growth inhibitory activity in multiple solid cancer models both
in vitro and in vivo and has been evaluated in a Phase 1 study (15,
17). In preclinical studies, the in vivo activity of enavatuzumab
was attributed to both direct stimulation of TweakR and Fc-
mediated antigen dependent cellular cytotoxicity (ADCC). The
mechanism of how enavatuzumab directly inhibited the growth of
tumor cells, and the cell signaling events occurring downstream of
enavatuzumab binding to TweakR were undefined, and therefore
became the primary focus of this study.
In this report we show that enavatuzumab activates the NFκB
pathway, and that its growth inhibitory activity is dependent on
NFκB. The finding that NFκB activation induced by the TweakR
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pathway drives the growth inhibitory activity of enavatuzumab
provides an interesting function for the NFκB family which is
more frequently associated with growth and survival of cancer
cells than their inhibition (18, 19).
MATERIALS AND METHODS
ANTIBODIES AND REAGENTS
Enavatuzumab (PDL192), 19.2.1, and the human IgG1 control
used in this study have been described previously (17). The
enavatuzumab-Fc mutant contains the L234A, L235A mutations
that reduce FcγR binding and ADCC. PDL400 (human IgG1) is
a humanized version of the previously described ITEM-4 (13).
Mouse anti-TweakR antibodies 136.1 (IgG1) and 18.3.3 (IgG2a)
were generated using the same strategy as that described for 19.2.1
(17). Antibodies were used at 10µg/mL for in vitro studies, unless
otherwise stated, and crosslinked with F(ab′)2 goat anti-human
IgG (Fcγ specific) from Jackson ImmunoResearch at 3.5µg/mL.
Recombinant human TWEAK was purchased from R&D Systems.
siRNAs were purchased from Thermo Scientific Dharmacon
and included the following: non-targeting control siRNA pool (D-
001810-10-05), p65 (RelA) siRNA pool (L-003533-00-0002) and
set of four individual siRNAs (LQ-003533-00-0002), p52/p100
(NFκB2) siRNA pool (L-003918-00-0002) and set of four indi-
vidual siRNAs (LQ-003918-00-0002), p50/p105 (NFκB1) siRNA
pool (L-003520-00-0002) and set of four individual siRNAs (LQ-
003520-00-0002), RelB siRNA pool (L-004767-00-0002) and set
of four individual siRNAs (LQ-004767-00-0002), IKKα (CHUK)
siRNA pool (L-003473-00-0002) and set of four individual siRNAs
(LQ-003473-00-0002), IKKβ siRNA pool (L-003503-00-0002)
and set of four individual siRNAs (LQ-003503-00-0002), p21
(CDKN1A) set of four individual siRNAs (LQ-003471-00-0002).
CELL LINES
All cell lines were obtained from the American Tissue Culture
Collection (ATCC) or National Cancer Institute (NCI), except
HSC-3 which was purchased from the Japan Health Science Foun-
dation and the MB231 variant cell line, which was derived from
the MDA-MB-231 cell line for its increased metastatic potential
in vivo.
CELL VIABILITY ASSAY
The 105 cell line panel was cultured at 500 cells per well in triplicate
with enavatuzumab or IgG1 control in the presence of F(ab′)2 goat
anti-human IgG (Fcγ specific) for 5 days in 96 well plates. Relative
cell viability was determined using CellTiter-Blue™(Promega).
Fluorescence emitted at 590 nm was used to calculate the growth
effect relative to the IgG1 control antibody treatment. Each cell
line was tested twice with the average growth inhibition reported.
LUCIFERASE TRANSCRIPTIONAL REPORTER ASSAY
The Cancer 10-Pathway Reporter Luciferase Kit was purchased
from SA Biosciences [CCA-101L (Plate Format)] and reverse
transfected into cells using Lipofectamine 2000 (Invitrogen). Cells
were treated with the indicated antibodies for 24 h following trans-
fection. Cells were harvested an additional 24 h later and reporter
activity was measured using the Dual-Luciferase Reporter Assay
(Invitrogen).
WESTERN BLOT ANALYSES
Whole cell protein lysates were generated using Cell Signaling
protein lysis buffer containing protease inhibitors (Roche) and
phosphatase inhibitor cocktail (Sigma), quantified using BCA
reagent (Pierce), and protein expression was detected using ECL
Plus Chemiluminescence kit (GE-Amersham). P-IκBα (Ser32/36)
5A5, p21 WAF1/CIP1 (DCS60), p65, p100/p52, p105/p50, and
RelB antibodies were purchased from Cell Signaling. GAPDH
antibodies were from Santa Cruz. Mouse and rabbit secondary
antibodies were from GE-Amersham.
NFκB TRANSCRIPTION FACTOR ELISA
TransAM™ NFκB family ELISA kit (Active Motif) was used to
determine NFκB subunit DNA binding and functional activity
in response to enavatuzumab treatment. Nuclear protein extracts
were generated and the subunit ELISAs (p65, p50, RelB, p52)
performed according to the manufacturer’s guidelines.
GENE CHIP ANALYSIS
RNA was isolated and purified with RNeasy Micro kits (Qiagen)
and analyzed using an Agilent 2100 Bioanalyzer RNA 6000. cDNA
was prepared from the RNA template, and used for in vitro tran-
scription in the presence of biotinylated nucleoside triphosphates.
The biotinylated RNA targets were fragmented, and hybridized
to a customized Affymetrix genechip platform (Eos Hu03plus)
using standard Affymetrix protocols. Genechips were performed
in duplicate and stained with streptavidin phycoerythrin (SAPE)
and scanned on an Affymetrix GeneChip Scanner 3000. Raw
data files were obtained after analysis of scanned images with
GCOS (GeneChip Operating Software, Affymetrix). Gene chip
expression data was generated according to previously described
methods (20). The microarray data contained within this man-
uscript is registered in the Gene Expression Omnibus (http:
//www.ncbi.nlm.nih.gov/geo/) and can be accessed using the GEO
submission GSE51934.
siRNA TRANSFECTIONS
OnTarget Plus pooled siRNA (15 nM) (Thermo Scientific) against
the target gene of interest or non-targeting pool control siRNA
were reverse transfected with Lipofectamine RNAiMax (Invit-
rogen) according to manufacturer’s protocol. A positive control
siRNA for successful transfection was also included (Kinesin Spin-
dle Protein, KSP). Target knockdown was maximally achieved
2 days post transfection. Cells were then treated with ena-
vatuzumab or IgG1 control+ crosslinking antibody for the time
indicated. The relative viability of the cells was determined, and
cells were also harvested for Western blot analyses.
IKK16 NFκB INHIBITION
The IκB kinase (IKK) selective inhibitor IKK16 (Tocris Bio-
science) was used at 160 nM (21). The IKK16 was added to
cells either alone or 1 h prior to addition of enavatuzumab
(10µg/mL)+ crosslinking antibody (3.5µg/mL). Cell viability
was determined 5 days post treatment.
CELL DIVISION ANALYSES
HT3 cells (30,000 cells per six-well) were siRNA transfected as
described above. Two days post transfection, CellTrace™ violet
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(Invitrogen) was added to the cells at 5µM for 30 min, cells were
washed according to the manufacturer’s instructions, and treated
with enavatuzumab or IgG1 control in the presence of crosslink-
ing antibody for 5 days. Cells were trypsinized and then fixed in
2% paraformaldehyde. The amount of CellTrace™ dye within the
cells was analyzed by flow cytometry using a violet laser (CyAn,
Dako).
XENOGRAFT GENERATION
ICR SCID mice (Taconic) were injected subcutaneously with 107
cells in RPMI media. Mice were randomized into groups when
the average tumor volume reached ~100 mm3. The animals were
injected with 10 mg/kg enavatuzumab or IgG1 control three times
per week (i.p.). Where p21 expression was to be analyzed by IHC,
mice received only a single dose of antibody. Animals were sac-
rificed at the various times indicated post-dose. Tumors were
harvested and flash frozen for protein or fixed in buffered forma-
lin and paraffin embedded. All animal protocols and procedures
were approved by the vivarium’s Institutional Animal Care and
Use Committee consistent with The U.S. Public Health Service
Policy on Humane Care and Use of Laboratory Animals (Office of
Laboratory Animal Welfare, National Institutes of Health).
IMMUNOHISTOCHEMISTRY
Xenograft samples were formalin fixed and paraffin embedded.
Tissue sections (5µm) were cut, mounted on slides, deparaf-
finized and ethanol rehydrated. Antigen retrieval was performed
using BORG Decloaker RTU (Biocare Medical). Primary anti-
bodies were p21 mIgG1 (Dako M7202) and cytokeratin18 rIgG1
(Abcam). Secondary antibodies were AlexaFluor488 goat anti-
rabbit and AlexaFluor594 goat anti-mouse (Invitrogen). Slides
were mounted in Vector Lab DAPI mounting medium and imaged
on a Zeiss Axioskop two fluorescent microscope. The number of
p21-positive cells in response to enavatuzumab or IgG1 control
was determined by counting three 40× magnification fields for
each xenograft tested.
RESULTS
ENAVATUZUMAB DISPLAYS BROAD GROWTH INHIBITORY ACTIVITY
IN VITRO
A panel of 105 cancer cell lines representing the majority of solid
tumor types was tested with enavatuzumab for in vitro growth
inhibitory activity in a 5-day proliferation assay, in the presence of
an anti-human F(ab′)2 to provide crosslinking of enavatuzumab
(Figure 1). Cell surface TweakR expression was confirmed in 103
out of 105 cell lines by flow cytometry (data not shown). Of the 105
cell lines tested, enavatuzumab displayed≥20% growth inhibitory
activity in 38 of the cell lines (37%). Of these cell lines, 29 (28%)
had ≥25% growth inhibition compared to cells treated with an
isotype control antibody. Sixty-five TweakR-expressing cell lines
were not sensitive to enavatuzumab, as indicated in Table 1. Ena-
vatuzumab displayed activity in a broad range of tumor types with
no single disease indication having notably superior sensitivity.
However, two of the small cell lung cancer lines tested, NCI-H69
and NCI-H146 did not express TweakR and were not sensitive to
enavatuzumab, demonstrating target specific activity.
FIGURE 1 | Enavatuzumab has growth inhibitory activity in a broad
range of cancer cell lines in vitro. One hundred and five cell lines
representing multiple solid tumor types were tested for sensitivity to
enavatuzumab in the presence of anti-human crosslinking antibody. The 38
cell lines that had ≥20% growth inhibition after 5-day treatment with
enavatuzumab are shown.
NFκB PATHWAY IS ACTIVATED IN RESPONSE TO ENAVATUZUMAB
TREATMENT
Multiple signaling pathways have been shown to be activated
downstream of TweakR, including NFκB, ERK, and JNK. NFκB,
in particular, has been suggested to play a pivotal role in the
context of tumor cell growth, as TWEAK upregulates the NFκB
signaling pathway in glioma cells where TWEAK also medi-
ates resistance to cytotoxic agents (22). To determine if NFκB
signaling might also be upregulated by TweakR agonists that
inhibit tumor growth, we transfected enavatuzumab sensitive
cells with a NFκB luciferase transcriptional reporter construct.
Upon enavatuzumab treatment, we observed a marked increase
in NFκB-driven luciferase expression in several cell lines, BT549
(Figure 2A), HCC38, A375, H358, and HT3 (data not shown).
To investigate further the activation of the NFκB pathway by ena-
vatuzumab, we next assessed the levels of phosphorylation of IκBα,
the cytoplasmic inhibitor of classical NFκB subunits. Phosphory-
lation of IκBα on Serine 32/36 has been shown to reflect NFκB
pathway activation, as it allows the cytoplasmic release and migra-
tion of NFκB dimers into the nucleus to initiate transcription
(18, 23, 24). In enavatuzumab sensitive cell lines, we consistently
observed phosphorylation of IκBα following enavatuzumab treat-
ment (Figure 2B). Degradation of IκBα was observed 30 min
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Table 1 | Enavatuzumab sensitivity did not correlate withTweakR expression.
Sensitive lines Resistant lines
Cell line Expression Cell line Expression Cell line Expression
CAMA-1 5.8 786-0 7.5 NCI-H187 3.9
SW780 16.1 A2058 3.8 NCI-H209 2.4
HCC38 10.7 A498 9.4 NCI-H226 4.8
Calu-6 14.2 BT20 5.3 NCI-H23 8.4
ACHN 9.8 BT-474 4.7 NCI-H292 12.0
HT3 15.2 BT-483 2.6 NCI-H322M 1.4
A253 11.6 C32 17.1 NCI-H345 2.4
NCI-ADR-RES 72.2 Calu-3 4.8 NCI-H460 3.7
SW480 55.0 COLO-205 1.9 NCI-H520 1.9
MDA-MB-231 4.8 DMS-79 2.1 NCI-H522 3.6
HCC70 2.1 DU-4475 3.9 NCI-H596 2.9
HT-29 18.5 HCC-1428 4.0 NCI-H69 1.2
HCC1500 5.2 HCC2998 5.4 NCI-H82 2.0
HSC-3 8.3 HCT-116 26.3 OVCAR4 15.9
HOP-62 10.3 HCT-15 16.0 OVCAR-5 1.4
MDA-MB-468 2.6 Hs 578T 5.1 OVCAR-8 55.3
BT549 5.6 HT1376 21.6 RXF393 6.2
MDA-MB-453 1.8 HT-144 5.0 SK-MEL-5 3.6
NCI-H358 11.6 IGROV-1 8.5 SKOV3 19.4
Malme-3M 11.4 KM12 2.2 SN12C 8.2
PA-1 17.4 LoVo 3.7 SR 1.7
SK-BR-3 4.2 LOXIMVI 11.3 SW48 8.9
HCC1143 10.2 M14 10.1 SW620 4.5
A549 16.4 MCF-7 11.3 SW626 9.2
NCI-H157 4.9 MDA-MB-157 6.3 SW948 12.8
OVCAR-3 9.2 MDA-MB-175-VII 2.3 T47D 4.7
HCC1569 3.9 MDA-MB-361 6.2 TK10 18.4
NCI-H1792 1.9 MDA-MB-435 4.7 U031 15.4
HOP-92 19.7 MDA-MB-435S 28.6 UACC-257 2.8
MB231 variant 19.8 MIA-PaCa-2 6.9 UACC62 11.0
EKVX 26.1 MX-1 11.9 WM-115 7.9
SK-MEL-28 14.2 NCI-H1155 2.0 ZR-75-1 3.1
HCC1937 5.3 NCI-H146 1.2 ZR-75-30 4.2
BxPC3 21.4 NCI-H1838 4.6
A375 8.9
CAKI-1 9.0
AsPC-1 3.6
SK-MEL-2 6.2
Sensitive lines (n=38) were defined as exhibiting at least 20% growth inhibition, and are arranged in order of sensitivity to enavatuzumab (see Figure 1). Resistant
lines showed <20% growth inhibition and included 65 TweakR-expressing lines and 2 non-expressing lines, italicized (NCI-H146 and NCI-H69). TweakR expression
was measured by enavatuzumab binding by flow cytometry and is reported as the fold increase in mean fluorescence intensity versus control antibody stained cells.
post enavatuzumab treatment, but this degradation was transient,
with IκBα expression being quickly re-established (Figure 2C).
The phosphorylation of IκBα was observed at later time points
4 and 24 h, indicating sustained activation of the NFκB path-
way, but this phosphorylation was not maintained at 48 and
72 h timepoints (Figure 2D). This phosphorylation event was
seen in all sensitive cell lines tested, with no marked change in
total IκBα expression at these time points (data not shown). In
HT3 cells, cleavage of p100 to the activated subunit p52 was
observed at 4 h and this activation was prolonged out to 72 h
(Figures 2C,D).
ENAVATUZUMAB INDUCES ELEVATED NFκB SUBUNIT ACTIVATION
AND INCREASED DOWNSTREAM TRANSCRIPTIONAL CHANGES IN
SENSITIVE COMPARED TO RESISTANT CELL LINES
Having established that NFκB was activated in response to
enavatuzumab treatment, we next performed NFκB functional
ELISAs across multiple cell lines to determine which specific NFκB
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FIGURE 2 |The NFκB pathway is activated in response to
enavatuzumab treatment in vitro. (A) A NFκB luciferase reporter
construct was transfected into BT549 cells, then treated with
antibody/crosslinker. Luciferase expression was measured 24 h post
antibody treatment. (B) NFκB activation was examined by Western blotting
for p-IκBα expression. Cell lysates were prepared at 4 and 24 h post
antibody treatment. C, samples treated with control antibody/crosslinker;
E, enavatuzumab/crosslinker-treated samples. (C,D) Enavatuzumab-
induced the NFκB pathway in HT3 cells. HT3 cells were treated with
enavatuzumab (E) or IgG1 control antibody (C) in the presence of
crosslinking antibody for the times indicated. Cell lysates were prepared
and activation of NFκB pathway members was analyzed by Western blot.
subunits were activated in response to enavatuzumab treatment.
The NFκB DNA binding ability of six sensitive cell lines (A375,
HCC38, H358, BT549, MDA-MB-468, and HT3) and three resis-
tant cell lines (UACC62, T47D, BT20) were examined by ELISA
post treatment (Figure 3A). Induction of all NFκB subunits (p50,
p65, p52, RelB, and c-Rel) was observed in sensitive cell lines fol-
lowing treatment. This indicates that both classical (p50, p65) as
well as non-classical (p52, RelB) NFκB pathways could be acti-
vated by enavatuzumab treatment. Interestingly, resistant cell lines
showed significantly less induction of all NFκB subunits, with little
or no subunit induction occurring in UACC62, T47D, and BT20.
The differential pattern of NFκB activation between ena-
vatuzumab sensitive and resistant lines was further confirmed
by gene chip microarray analysis. The number of genes up- or
down-regulated >2-fold was greater in sensitive lines (BT549,
MDA-MB-468) compared to those in resistant lines (T47D, BT20)
(Table 2). For example, 408 genes were up- or down-regulated in
sensitive BT549 cells after 24 h of treatment,while the expression of
only 9 genes changed in the resistant T47D cells at this timepoint.
Many of the transcriptional changes were for genes known to be
regulated by NFκB (Figure 3B). Known NFκB pathway members
and NFκB-regulated genes, as defined by GSES, are induced by
enavatuzumab in BT549 cells. In contrast, few NFκB-regulated
genes were induced in the T47D resistant cell line. Upregulation
of NFκB-regulated genes was seen across all the time points in the
BT549 gene chip, while for T47D, activation of the few NFκB-
regulated genes appeared to be more delayed, and were often
different genes than those in the sensitive lines.
NFκB ACTIVATION IS SEEN IN VIVO FOLLOWING ENAVATUZUMAB
TREATMENT
To determine whether NFκB was activated in vivo in response to
enavatuzumab treatment, we selected the enavatuzumab sensitive
H358 xenograft model, as H358 cells displayed strong NFκB activa-
tion and growth inhibition by enavatuzumab in vitro. In addition,
enavatuzumab exhibited 70% tumor growth inhibition (TGI) of
H358 tumors in vivo. In this model, response to enavatuzumab
was dependent on signaling through TweakR, as a version of
enavatuzumab containing a mutation in the Fc region that pre-
vents antibody-dependent cellular cytotoxicity, exhibited equiva-
lent activity as wild-type enavatuzumab (Figure 4A). Other sen-
sitive lines, including HT3 and BT549, did not form xenografts in
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FIGURE 3 | Differential NFκB pathway activation in sensitive
compared to resistant cell lines. (A) NFκB functional DNA binding
ELISAs were performed on sensitive (black bars) and resistant (gray
bars) cell lines. The relative level of subunit binding (y -axis) was
calculated by subtracting the OD450 of the control samples from that of
the enavatuzumab-treated samples. (B) Enavatuzumab-induced
changes in gene expression were measured 6–72 h after antibody
treatment by gene expression profiling. The average of duplicate
samples is shown for each time point treated with enavatuzumab or
IgG1 control in the presence of a crosslinking antibody. Changes in
NFκB responsive genes are shown for a sensitive (BT549) and resistant
(T47D) cell line.
Frontiers in Immunology | Inflammation January 2014 | Volume 4 | Article 505 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Purcell et al. Enavatuzumab inhibits tumors through NFκB
Table 2 | Enavatuzumab treatment induced more gene expression
changes in sensitive cell lines than in resistant lines.
Number of genes up or down >2-fold
Sensitive lines Resistant lines
MDA-MB-468 BT549 T47D BT20
6 h 51 126 1 nt
24 h 50 408 9 nt
48 h 329 648 15 3
72 h 445 766 13 nt
The total number of genes whose expression is altered more than twofold up or
down following enavatuzumab treatment at each time point is displayed.
nt, not tested. Analysis of BT20 cells was performed only at 48 h.
our hands. In H358 tumors harvested from enavatuzumab-treated
mice, an increase in the levels of NFκB subunits RelB, p105/p50,
and p52 was observed (Figure 4B), indicating activation of
the NFκB pathway. No change in p65 expression was observed
following enavatuzumab treatment in this model.
INHIBITION OF NFκB PATHWAY MEMBERS REDUCES
ENAVATUZUMAB-DRIVEN CANCER GROWTH INHIBITION
Having shown that enavatuzumab treatment upregulates NFκB
pathway activation, we next assessed whether NFκB signaling was
important for enavatuzumab’s growth inhibitory activity. siRNA
experiments were performed to knock down components of the
NFκB pathway,after which cells were assessed for sensitivity to ena-
vatuzumab. siRNAs to multiple NFκB pathway members, includ-
ing the upstream kinases IKKα (CHUK) or IKKβ significantly
reduced the sensitivity of cell lines to enavatuzumab (Figure 5A).
To confirm the role of the NFκB pathway in growth inhibition by
enavatuzumab, a small molecule inhibitor (IKK16) of the NFκB
upstream kinases IKKα/β was also found to reduce growth inhibi-
tion by enavatuzumab in multiple cell lines (Figure 5B). Assessing
the impact of siRNA knockdown of individual NFκB subunits
(p65,p52,RelB,and p50) showed a differential reduction in growth
inhibition by enavatuzumab. siRNA inhibition of p52 expres-
sion reduced enavatuzumab growth inhibition in MDA-MB-468
cells, while BT549 cells primarily showed a dependency on p50
and p65 for enavatuzumab activity (Figure 5C). Knockdown of
RelB was found to reduce enavatuzumab growth inhibition in
other cell lines, including HT3 (data not shown). The importance
of each particular subunit for the observed growth inhibition
varied between cell lines and did not necessarily correlate with
induction of subunit expression or activation by enavatuzumab
(Figures 3A,B).
We next investigated the mechanism by which enavatuzumab
inhibits tumor cell growth inhibition through NFκB. The rate
of cell proliferation in enavatuzumab-treated cells was assessed
using CellTrace™ dye. The dye contained within the labeled cells
is diluted when passed to daughter cells during cell division, result-
ing in reduced fluorescence in the progeny. HT3 cells treated with
enavatuzumab exhibited higher fluorescence than control-treated
cells, suggesting that they divided less frequently (Figure 5D).
Inhibition of cell division by enavatuzumab was shown to be
NFκB-dependent by using siRNAs against individual NFκB sub-
units (p50, p65, RelB, p52). Knockdown of each of these NFκB
subunits allowed HT3 cells to divide more frequently, thereby
overcoming inhibition of cell division by enavatuzumab.
ENAVATUZUMAB CAUSES AN NFκB-DEPENDENT UPREGULATION OF
THE CELL CYCLE INHIBITOR p21
To characterize further the mechanism of cell growth inhibi-
tion by enavatuzumab, we next assessed whether inhibition of
cell division might be achieved by altering cell cycle regulators.
One well characterized NFκB-regulated cell cycle inhibitor is p21
(WAF1/CIP1) (25, 26). The expression of p21 was found to be
upregulated in multiple sensitive cell lines after enavatuzumab
treatment (Figure 6A). To confirm that p21 upregulation by ena-
vatuzumab was mediated by NFκB, siRNAs against p65 and p52
were transfected into HT3 cells, after which they were treated with
enavatuzumab. While siRNAs to both p65 and p52 downmodu-
lated expression of their cognate proteins, they had little/no effect
on the expression of the other subunit (Figure 6B). However, p21
upregulation by enavatuzumab was blocked by siRNAs to both
p65 and p52, suggesting that p21 induction was NFκB-dependent.
The ability of other TweakR agonists to effect p21 upregulation
was also evaluated. Multiple TweakR agonists, including the ligand,
TWEAK, and TweakR targeting antibodies with differing signal-
ing potentials, including weak (PDL400, 18.3.3), moderate (19.2.1
and enavatuzumab), and strong (136.1) agonists, were all able to
upregulate p21 in HT3 cells (Figure 6C), suggesting that TweakR
stimulation by a variety of agonists activates common downstream
signaling pathways.
To determine whether p21 upregulation was important for
growth inhibition mediated by enavatuzumab, BT549 cells trans-
fected with p21 siRNAs were treated with enavatuzumab. Knock-
down of p21 expression reduced the ability of enavatuzumab to
inhibit the growth of BT549 cells by ~20% (Figure 6D). Taken
together, these results suggest that growth inhibition by TweakR
agonists is mediated by p21 upregulation, which is, in turn, driven
by NFκB pathway activation.
Having shown that enavatuzumab-mediated growth inhibition
by upregulating p21 in vitro, enavatuzumab was next evaluated for
its ability to induce p21 in vivo. H358 xenografts were treated with
a single dose of enavatuzumab, after which tumors were harvested
and stained for p21 by immunohistochemistry (Figure 7A). Ena-
vatuzumab treatment resulted in an increase in p21-positive cells
that was observed 3 days after dosing, and was maintained for at
least 1 week after a single i.p. dose of enavatuzumab (Figure 7B).
DISCUSSION
In this study we have demonstrated that enavatuzumab caused a
growth inhibitory effect on many cancer cell lines, across a range
of tumor types. This agrees with the broad in vivo activity seen
in xenograft models (17) and supports the investigation of ena-
vatuzumab as a therapeutic modality in solid tumors. Growth
inhibition and signaling was enhanced through the crosslinking
of enavatuzumab. This implies that TweakR oligomerization is
important for enavatuzumab-mediated growth inhibition and for
the signaling that occurs downstream of the receptor. This agrees
www.frontiersin.org January 2014 | Volume 4 | Article 505 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Purcell et al. Enavatuzumab inhibits tumors through NFκB
FIGURE 4 | In vivo efficacy and NFκB activation in H358 xenografts in
response to enavatuzumab. (A) H358 xenograft tumors at ~100 mm3 in ICR
SCID mice were treated i.p. with enavatuzumab, enavatuzumab-Fc mutant, or
IgG1 control at 10 mg/kg q3w as indicated. (B) H358 xenografts were treated
on days 0 and 3 with enavatuzumab or control antibody. Tumors from three
mice from each treatment group were excised on day 4, after which cell
lysates were prepared and analyzed by Western blot. Activation of NFκB was
examined by measuring RelB, p105/p50, p52, and p65 levels in the tumors.
with previous reports assessing TweakR activation with agonist
antibodies (15, 27).
It should be noted that the extent of cell surface expression
of TweakR did not correlate with in vitro activity, as discussed
previously (15, 17). Therefore the highest TweakR-expressing cell
lines were not necessarily the most enavatuzumab sensitive. This
is likely due to the pleiotropic functions of TweakR and reveals a
degree of complexity regarding the relationship between receptor
expression and function that requires further investigation.
The induction of NFκB in response to enavatuzumab stim-
ulation of TweakR agrees with findings in the literature for
the receptor’s natural ligand TWEAK (2, 9, 28). Like TWEAK,
enavatuzumab activated both classical and non-classical NFκB
pathways. Previous reports have demonstrated transient activa-
tion of p50/p65 NFκB subunits and a more sustained activation
of the non-classical p52/RelB subunits in response to TWEAK
(29, 30). Interestingly we observed phosphorylation of the NFκB
inhibitor IκBα up to 24 h post enavatuzumab treatment. This indi-
cates prolonged activation and continual re-expression of IκBα
despite NFκB activation. This contrasts with what is observed
with TNFα, where IκBα is rapidly phosphorylated and degraded
leading to transient activation of NFκB (31). We also saw acti-
vation of p52 up to 72 h post addition of enavatuzumab. The
finding that NFκB pathway induction was observed several days
post enavatuzumab treatment by Western blot and microarray
analyses indicates some possible differential activity between that
of TweakR’s ligand TWEAK and enavatuzumab.
Transient versus persistent NFκB activation can result in differ-
ent gene induction profiles in response to TNFα and LPS, resulting
in contrasting protein expression and varying growth and sur-
vival phenotypes (32, 33). Therefore continual signaling through
TweakR by enavatuzumab may induce different NFκB-regulated
genes than when TWEAK binds TweakR. Also, it has been pre-
viously reported that TWEAK can be internalized (10, 34), and
like other TNF family members, the cell surface expression of
the receptor TweakR is likely to be tightly regulated/internalized
upon ligand stimulation (35, 36). In contrast, antibody binding
to TweakR maintains cell surface expression of TweakR (data
not shown), which may lead to the observed prolonged recep-
tor activation and sustained stimulation of downstream signaling
pathways, such as NFκB. Alternatively, the crosslinking of ena-
vatuzumab may aid in prolonging the signaling downstream of
TweakR which could explain differences in persistence of signaling
seen with TWEAK ligand versus enavatuzumab. Such a relation-
ship between antibody crosslinking and downstream signaling has
been described previously (37).
Cell lines sensitive to enavatuzumab displayed more NFκB
activation, as seen by subunit functional ELISA, compared to
resistant cell lines. Resistant cell lines also showed a delayed
and reduced induction of NFκB-regulated genes. Gene expres-
sion analysis revealed strong induction of many NFκB-regulated
genes across all time points tested (6–72 h), while T47D cells had
little induction of the same NFκB-regulated genes, especially at
the earlier time points. Sensitive cell lines showed 400–700 genes
up or down-regulated >2-fold following enavatuzumab treat-
ment, while resistant cells exhibited changes in expression in fewer
than 20 genes, indicating that significant transcriptional activity
occurred in sensitive cell lines, which was not observable in the
resistant setting. A small number of NFκB-regulated genes were
induced in the T47D cell line, which were not induced in BT549
cells, which may suggest that some of these genes may play a role in
the resistant phenotype, but their role, if any, is unclear. In general,
it appears that sensitive cell lines exhibit increased overall activa-
tion of NFκB signaling by enavatuzumab, and these changes could
potentially be useful when selecting patients and measuring their
response. Therefore, understanding the molecular changes down-
stream of TweakR signaling in the sensitive/resistant settings is of
great interest.
We demonstrated that the NFκB activation observed in
response to enavatuzumab was essential for its growth inhibitory
activity. siRNA targeting of specific NFκB subunits (p50, p65, p52,
RelB) abrogated the growth inhibition, however different cell lines
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FIGURE 5 | Inhibition of NFκB activation prevents the growth
inhibitory activity of enavatuzumab. (A) BT549 cells were transfected
with two different siRNAs against p65 or upstream kinases IKK1 (IκBKβ),
IKK2 (CHUK). Transfection controls were non-targeting control (negative)
or KSP (positive control for transfection efficiency). After 48 h, cells were
treated with enavatuzumab or IgG1 control at 10µg/mL for an additional
5 days in the presence of anti-human crosslinking antibody (3.5µg/mL),
and the cell viability was determined. siRNA significantly reduced growth
inhibition by enavatuzumab, compared to mock or control siRNA
transfected cells (horizontal line) (*p-value<0.05). (B) Enavatuzumab
sensitive lines were treated with IKK inhibitor IKK16 at 160 nM (black
bars), enavatuzumab/crosslinker (gray bars), or IKK16 plus
enavatuzumab/crosslinker (striped bars) and % survival was measured
after 5 days. IKK16 significantly blocked growth inhibition by
enavatuzumab compared to enavatuzumab alone (*p-value< 0.05).
(Continued)
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FIGURE 5 | Continued
(C) Targeting individual NFκB subunits (p50, p65, RelB, p52) by siRNA
reduced enavatuzumab activity in sensitive cell lines (MDA-MB-468 and
BT549). Cells were transfected with pooled targeting siRNA or control
siRNA for 48 h, prior to treatment with enavatuzumab or IgG1 control for
5 days in the presence of a crosslinking antibody. Percent survival was
calculated from the relative viability of cells treated with enavatuzumab
versus control-treated cells (*p-value<0.05). (D) The effect of NFκB
induced by enavatuzumab on cell division was investigated by pre-labeling
HT3 cells with the Cell Trace™ reagent. Cells treated with enavatuzumab/
crosslinker (green line) are compared to the IgG1 control-treated cells (red
line). Cells transfected with two different siRNAs to p65, p50, p52, or RelB
and treated with enavatuzumab/crosslinker (blue and brown lines) are also
displayed.
FIGURE 6 | Enavatuzumab inhibits cell division and upregulates p21
in vitro and in vivo in an NFκB-dependent manner. (A) Sensitive cell
lines HT3, BT549, MALME-3M, H358, BXPC3, and A253 were treated
with IgG1 control antibody (C) or enavatuzumab (E) for 4–72 h in the
presence of crosslinking antibody, after which p21 expression was
assessed by Western blot. (B) The role of NFκB in enavatuzumab-induced
p21 expression was examined by knocking down the expression of p65 or
p52 with two different siRNAs to each. Samples were transfected with
siRNA for 24 h, then treated with IgG1 control or enavatuzumab for an
additional 24 h in the presence of crosslinking antibody. Cell lysates were
analyzed by Western blot for p21, p52, and p65 expression. (C) p21 is
activated by multiple antibodies targeting TweakR targeting and TWEAK
ligand. HT3 cells were treated (10µg/mL) with antibodies that bind and
activate TweakR including enavatuzumab, PDL400, 136.1, 19.2.1, 18.3.3,
or TWEAK ligand (300 ng/mL) for 24 h in the presence of crosslinking
antibody. p21 expression was then assessed by Western blot. (D) siRNA
inhibition of p21 reduces the relative growth inhibition caused by
enavatuzumab treatment. BT549 cells were transfected with four different
siRNA oligos targeting p21. Two days post transfection, cells were treated
with enavatuzumab for 5 days in the presence of crosslinking antibody and
cell viability was determined. Relative viability of 1.0 represents the
viability of cells transfected with the non-targeting control siRNA and
treated with enavatuzumab. An increase above 1.0 in cells transfected with
p21 siRNAs indicates an increase in cell viability relative to the control
siRNA transfected cells (p<0.05). Control transfected cells treated with
the IgG1 control antibody exhibited a relative viability of 3.75.
were more sensitive to inhibition of certain subunits than others.
For example, HT3 cells were dependent on non-classical (p52/Rel
B) NFκB activation, while BT549 cells relied more on the classical
NFκB (p50/p65) pathway for enavatuzumab growth inhibition.
All sensitive cell lines showed a marked increase in the expression
of NFκB subunits by enavatuzumab, but there was no clear pattern
of subunit induction in response to enavatuzumab treatment, and
the induction did not always correlate with siRNA subunit sen-
sitivity. It should be noted however, that we were able to reduce
enavatuzumab activity in every sensitive cell line by inhibiting
at least one or more NFκB subunits. Therefore, there does not
appear to be a single reliance on either the classical or non-classical
NFκB pathways for enavatuzumab activity, but is likely to com-
prise a complex combination of cellular events involving cross-talk
and interdependency between both pathways that requires further
examination.
Enavatuzumab-induced growth inhibition of many cancer cell
lines, but the characteristics of this growth inhibition had not
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FIGURE 7 | Enavatuzumab treatment of H358 xenograft tumors results in
p21 upregulation in vivo. (A) H358 xenografts were grown in ICR SCID
mice to ~100 mm3 and mice were then treated with a single i.p. injection of
IgG1 control or enavatuzumab at 10 mg/kg. Tumors were excised and the
levels of p21 were determined by multi-color IHC. A representative image
with p21 expression in red, cytokeratin in green, and nuclei in blue is shown
(40× magnification). (B) Quantification of p21 expression from H358
xenografts excised on days 1, 2, 3, and 7 post treatment. Data points
represent a single 40× magnification field with three fields for three individual
xenografts analyzed per time point for each treatment (p<0.001 IgG1 control
versus enavatuzumab days 3 and 7). The y -axis represents quantification of
p21+ cells in arbitrary units.
previously been described. We found that enavatuzumab treat-
ment resulted in a marked reduction in cell division. In HT3 cells,
siRNA inhibition of p50, p52, and RelB in the context of ena-
vatuzumab treatment helped restore the number of cell divisions
to that seen with IgG1 control. This further confirmed NFκB’s
critical role in enavatuzumab’s growth inhibitory activity.
When we evaluated the possible causes of the cell division block
caused by enavatuzumab, we found that the key cell cycle reg-
ulator p21 was induced following treatment in many responder
cell lines both in vitro and in H358 xenografts in vivo. The pro-
longed in vivo upregulation of the cell cycle inhibitor p21, up
to 7 days after a single antibody dose, is a compelling growth
inhibitory mechanism of enavatuzumab and is a novel activity for
a TweakR-targeted therapeutic. p21 was found to be upregulated
by multiple TweakR-targeted molecules that have different levels
of agonism, suggesting a common mechanism of growth inhibi-
tion by diverse agents that activate the TweakR signaling pathway.
We were able to block enavatuzumab-driven p21 upregulation by
inhibiting specific NFκB subunits. Inhibition of p52 in particular,
resulted in complete loss of p21 induction in HT3 cells, further
supporting the importance of the non-classical NFκB pathway for
enavatuzumab’s activity in this cell line.
It has been reported that TweakR activation can result in
growth inhibition by NFκB-mediated upregulation of TNF and
subsequent apoptosis via TNFR1 in some cell lines (e.g., Kym-
1, OVCAR4, SKOV3) (38, 39). Interestingly, two of these cell
lines, OVCAR4 and SKOV3 were included in our screen and were
found not to be sensitive to enavatuzumab. However, because
not all enavatuzumab sensitive cell lines were assessed for p21
upregulation, it is possible that additional mechanisms, including
TNF-mediated apoptosis,may be involved in the growth inhibition
by enavatuzumab. This question warrants further evaluation.
The NFκB-dependent growth inhibitory activity of ena-
vatuzumab is an interesting finding for a family of transcription
factors frequently associated with growth and survival in cancer
(40–42). However, the diversity and complexity of NFκB signaling
suggests that NFκB can inhibit the growth of tumor cells under
certain circumstances (43).
Therefore, our finding that the growth inhibitory activity of
enavatuzumab is driven in large part by NFκB suggests that
the targeted activation of the NFκB pathway may be a novel
therapeutic approach for treating cancer. In summary we have
outlined how NFκB activation and induction of downstream sig-
naling events, including p21, are essential for the TGI mediated by
enavatuzumab.
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